Sacran, a new sulfated glycosaminoglycan-like polysaccharide from river alga Aphanothece sacrum (Suringar) Okada alleviates hemorrhoid syndrome: Case report

Nlandu Roger Ngatu*,****, Maiko Kaneko Okajima**,****, Luzitu Severin Nganaga******
Samuel Vumi-Kiaku******, ******, Tatsuo Kaneko**,****, Sakiko Kanbara*, Roger Di-Mosi Wumba*******
and Stanislas Wembonyama-Okitotsho********

* Graduate School of Health and Nursing Sciences, University of Kochi, Kochi, Japan.
** School of Materials sciences, Japan Advanced Institute of Science and Technology, Nomi, Japan.
**** Congo Heiwa-Mura (Heath & Education N.P.O.).Kongo central, Democratic Republic of the Congo;Yungnam University, Gyeongbuk, Republic of Korea.
***** Department of Tropical Medicine&Parasitology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo;
****** Department of Health Sciences, InstitutUniversitaire des Sciences de Sante (I.U.S.S), Labumbashi, Democratic Republic of the Congo.

Received July 1, 2015: Revised July 20, 2015: Accepted July 25, 2015: Published online December 30, 2015

Abstract
Hemorrhoids are a common inflammatory anorectal disorder that affects millions of people worldwide. Its etiology is multifactorial, including chronic constipation, prolonged strain, thus suggesting the role of lifestyle, diet and occupation in the development of the disease. We report on cases of patients with hemorrhoids who took part in a preliminary study. In total, there 13 participants, including 7 patients treated with the anorectal application of 1% sacran and 6 others treated with Rectosol suppository administered twice daily for at least 2 weeks. Clinical severity of hemorrhoid symptoms was evaluated at baseline and 2 weeks later with the use of a prepared and validated questionnaire. The results showed that anorectal application of 1% sacran could relieve hemorrhoid syndrome as efficiently as Rectosol, with a better effect on constipation and pruritus (itch) (p<0.01) than Rectosol. Findings from this preliminary clinical trial suggest that sacran has a potential to improve symptoms of hemorrhoidal disease.

Key words: Aphanothece sacrum, glycosaminoglycan, hemorrhoidal disease, sacran

1. Introduction
Hemorrhoids, a common inflammatory anorectal disorder that involves hemorrhoid plexus, are a symptomatic enlargement and distal displacement of the normal anal cushions that affects millions of people worldwide (Lohsiriwat, 2012). Patients with hemorrhoid syndrome often consult a physician only after the disease symptoms get unbearable. The etiology of hemorrhoids is multifactorial and includes chronic constipation, prolonged strain (Lohsiriwat, 2012; Loder et al., 1994; Kayhan et al., 2008), suggesting the role of lifestyle, diet and occupation in the development of the disease.

A variety of substances are currently in use for the treatment of hemorrhoids such as anti-inflammatory (corticosteroids), anesthetic (xylocaine), venoconstrictive (diosmin) agents (Kayhan et al., 2008) and plant-based products. Other treatment procedures include injection sclerotherapy, rubber band ligation (RBL), cryotherapy, infrared photocoagulation, laser therapy and hemorrhoidectomy (surgery) (Dennison et al., 1996). In the Democratic Republic of the Congo (DRC), there is still an important fraction of population that utilizes ethnomedicine remedies (mostly plant-based products) for chronic diseases such as hemorrhoids (Ilumbe, 2014).

Sacran is a new bioactive sulfated glycosaminoglycan isolated from Aphanothece cesarum (Suringar) Okada, a river alga currently mass-cultivated in the western Japanese region of Kyushu. Previous studies have shown that sacran improves the skin barrier and exerts anti-inflammatory effects on skin allergic disorders (Okajima et al., 2009; Ngatu et al., 2012). In addition, findings from a recent research suggest that sacran could be useful in drug delivery for topically administered medications (Motoyama, 2014). Recently, we have gathered a number cases of hemorrhoid patients whose conditions have been improved after 3 to 5 days of anal application of sacran solution (Ngatu, 2014; unpublished). In the present preliminary clinical study, we evaluated the clinical benefit of sacran on hemorrhoid syndrome in African patients in comparison with Rectosol® suppository, one of widely used anti-hemorrhoid agents in Kinshasa.

2. Materials and Methods
2.1 Study design and patients
A pilot preliminary patient-blinded controlled clinical trial (non-randomized) was implemented from October through December 2013 in which a consecutive sample of 15 male adult Congolese

---

Key points:
- Sacran is a new sulfated glycosaminoglycan-like polysaccharide isolated from a river alga.
- It was evaluated for its potential to alleviate hemorrhoid symptoms.
- A pilot clinical trial compared sacran with Rectosol® suppository.
- Findings suggest sacran is as effective as Rectosol in relieving hemorrhoid symptoms.
- This study highlights the potential of ethnomedicine remedies for modern treatment.

---
patients, mainly office workers and mechanics, from the western district of Tshangu in Kinshasa, Democratic Republic of the Congo, participated.

2.2 Sacran extraction and chemical structure

Sacran was extracted by the alkaline dissolution of acid-washed biomaterials of Aphanothece sacran as previously described (Ngatu et al., 2012), and an aqueous solution of 1% sacran was prepared and used in this preliminary study. The Figure 1 below shows the main chemical structure and composition of sacran chains.

![Figure 1: Main structure of sacran chains with the sequences in monosaccharide triads and glycoside linkages](image)

2.3 Enrollment and clinical evaluation of disease severity

Entry criteria were as follows: voluntary participation upon submission of a written and signed informed consent form, having a documented diagnosis of internal and/or external hemorrhoids and confirmation by the investigator after a clinical examination, not using a concurrent medication at the time of enrollment and duration the follow-up period. The grading of hemorrhoidal disease was performed using four grades (grade 1, 2, 3 and 4) as described previously (Banov et al., 1985). Patients were requested to fill-in a self-evaluation form (French version), at baseline and on eighth and fourteenth (7 days of interval).

The patient’s form had a list of common hemorrhoid symptoms (anal pain, anal bleeding, constipation, itch, swelling or lump and prolapse); a 4-scale severity was considered for each individual symptom: 0, absence; 1, mild; 2, moderate and 4, severe. The hemorrhoid syndrome severity based on symptoms severity score according to patient’s self-evaluation was the outcome variable of this study. Of the 15 patients enrolled, two (1 from sacran group and another one from Rectosol® group) were excluded as they did not show up during periodical evaluations; thus, the final sample size was 13 (7 sacran-treated patients and 6 controls or Rectosol patients).

2.4 Treatments

In this trial, 1% sacran aqueous solution was used as treatment, applied in and out of anus; whereas 2.5% Rectosol® suppository was the control anti-hemorrhoid agent. Rectosol® is one of the most commonly used anti-hemorrhoid drugs in Kinshasa and it mainly contain hydrocortisone as principal active molecule. The treatment was administered twice daily; sacran aqueous solution was administered through anorectal application. Participation was voluntary and only patients who were not under other anti-hemorrhoid medication were recruited, and a combination of two agents was not allowed.

2.5 Ethical consideration and data analysis

For this preliminary study, ethical approval was obtained from the academic research ethics review board of the Department of Health Sciences of the Institut Superieur Technique Songwa (I.S.T.S.), Kinshasa, Democratic Republic of the Congo. In addition, signed informed consent form was provided by each of the participants prior to responding to interview questionnaire. Data are expressed as total severity score; for each treatment arm; the total severity score at baseline (start of treatment) and two weeks later were compared using Fisher’s exact test. Stata software version 11.0 (Stata corp., TX, USA) was used for data analysis.

3. Results and Discussion

3.1 Demographic, occupational characteristics and baseline disease severity of the patients

Table 1 shows the demographic, occupational characteristics and disease severity grade according the investigator. Of the 13 patients, 11 were males whereas the remaining two others were females. The mean age of the patients was 34.9 ± 13.5, with the oldest aged 71 years and 22 for the youngest. There were six patients with severe hemorrhoid syndrome (severity level 3), including five patients in the sacran group. Six patients were office workers involved in computer work and four were mechanics. In terms of clinical classification in grades, the majority of patients were of grade II hemorrhoid disease (internal hemorrhoid, prolapse during defecation with spontaneous reduction) (Banov et al., 1985). One patients was a retired soldier and two were employed at the time of this study (Table 1).

<table>
<thead>
<tr>
<th>Patient’s code</th>
<th>Gender</th>
<th>Age (y)</th>
<th>Marital status</th>
<th>Occupation</th>
<th>Disease severity (1-3)</th>
<th>Treatment group</th>
</tr>
</thead>
<tbody>
<tr>
<td>KO1</td>
<td>M</td>
<td>71</td>
<td>M</td>
<td>Retired</td>
<td>3</td>
<td>Sacran</td>
</tr>
<tr>
<td>MA12</td>
<td>M</td>
<td>30</td>
<td>S</td>
<td>Office work</td>
<td>1</td>
<td>Rectosol</td>
</tr>
<tr>
<td>MA3</td>
<td>M</td>
<td>43</td>
<td>M</td>
<td>Mechanic</td>
<td>2</td>
<td>Sacran</td>
</tr>
<tr>
<td>SU4</td>
<td>M</td>
<td>22</td>
<td>S</td>
<td>Mechanic</td>
<td>3</td>
<td>Sacran</td>
</tr>
<tr>
<td>DO5</td>
<td>M</td>
<td>28</td>
<td>S</td>
<td>Mechanic</td>
<td>1</td>
<td>Rectosol</td>
</tr>
<tr>
<td>ME11</td>
<td>F</td>
<td>47</td>
<td>S</td>
<td>Office work</td>
<td>1</td>
<td>Sacran</td>
</tr>
<tr>
<td>EO7</td>
<td>M</td>
<td>28</td>
<td>M</td>
<td>Unemployed</td>
<td>3</td>
<td>Rectosol</td>
</tr>
<tr>
<td>LO8</td>
<td>M</td>
<td>22</td>
<td>S</td>
<td>Office work</td>
<td>1</td>
<td>Rectosol</td>
</tr>
<tr>
<td>LO9</td>
<td>M</td>
<td>37</td>
<td>M</td>
<td>Unemployed</td>
<td>3</td>
<td>Sacran</td>
</tr>
<tr>
<td>IS10</td>
<td>M</td>
<td>27</td>
<td>S</td>
<td>Office work</td>
<td>3</td>
<td>Sacran</td>
</tr>
<tr>
<td>MA6</td>
<td>F</td>
<td>30</td>
<td>M</td>
<td>Office work</td>
<td>2</td>
<td>Rectosol</td>
</tr>
<tr>
<td>KO2</td>
<td>M</td>
<td>43</td>
<td>S</td>
<td>Mechanic</td>
<td>3</td>
<td>Sacran</td>
</tr>
<tr>
<td>EO13</td>
<td>M</td>
<td>26</td>
<td>S</td>
<td>Office work</td>
<td>1</td>
<td>Rectosol</td>
</tr>
</tbody>
</table>

Foot notes: M = male or married; F = female; S = single; y = years

3.2 Effects of sacran and rectosol on hemorrhoid syndrome according patients’ self-evaluation of symptoms severity

Figure 1 shows the trend of total severity score of hemorrhoid syndrome. After a 2-week period of treatment, patients treated with 1% sacran saw their symptoms relieved quite earlier as compared with those in Rectosol group; however, the difference was not significant (p>0.05). When each of treatment group was considered separately for the severity score at baseline and 2 weeks later, both Rectosol and Sacran could significantly reduce the total
severity score of hemorrhoid syndrome (100% and 26%; 100% and 16% for Rectosol and Sacran, respectively; p<0.001) (Figure 2).

Figure 2: Trend of total severity of hemorrhoid syndrome among Sacran and Rectosol-treated patients

3.3 Effects of sacran on the severity of constipation, anal bleeding, anal pain and itch

Regarding common hemorrhoid symptoms, most patients in sacran group had constipation, anal bleeding and itch; whereas a higher number of Rectosol patients had anal pain. sacran markedly relieved constipation and itch as compared with Rectosol (p<0.01). On the other hand, both sacran and Rectosol had similar beneficial effects on anal pain and anal bleeding (p>0.05). When considering the symptom severity score at baseline and 2 weeks later for each treatment group separately, both sacran and Rectosol significantly reduced the severity of constipation, anal bleeding, anal pain and itch (p<0.01). Though an improvement was observed in both treatment groups, no significant change was observed when comparing the total severity score for lumps or swelling (p>0.05) after 2 weeks of treatment (not shown).

Figure 3: Trend of total severity score for constipation, anal bleeding, anal pain and itch

The present preliminary clinical study investigated the beneficial therapeutic effects of sacran, a sulfated glycosaminoglycan with anti-inflammatory effects, in a small sample of patients with mild to severe hemorrhoid syndrome. The results showed that anorectal application of 1% sacran could relieve hemorrhoid syndrome as efficiently as Rectosol, with a better effect on constipation and pruritus (itch) than Rectosol. Constipation is considered as one of the etiologic factors as well as a common symptom of hemorrhoid disease (Abramowitz et al., 2001); its relief by sacran suggests that this new natural product (sacran) could improve bowel function. A part from its anti-inflammatory effects, sacran has a good coating effect (Ngatu et al., 2012), which may explain the relief of anal bleeding in patients. The principal limitation of this study is the small sample size (13 patients) and the fact that the main outcome measurement derives from patients’ self-evaluation of disease severity, which may differ from patient to patient. Nonetheless, the present case report shows the potential of sacran to improve hemorrhoid syndrome. Another study with a larger sample size should be envisaged to determine.

Acknowledgments

The authors thank Ir Jules MbalaNzobadila and Mr Kei Tanaka who supported this study.

Conflict of interest

We declare that we have no conflict of interest.

References


